No Data Yet
Arcus Biosciences announced its CEO, Terry Rosen, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Gilead's Kite unit reported positive new analysis for its Yescarta cell therapy as a second-line lymphoma treatment, reinforcing its oncology franchise. The win provides a crucial boost as the company navigates a major setback in its lung cancer pipeline, highlighting the high-stakes nature of its diversification strategy.
Immunovant is now prioritizing its next-generation antibody, IMVT-1402, for Graves' Disease, following a successful $550M capital raise. This strategic pivot sharpens the company's clinical focus and solidifies its financial runway through potential commercialization.
Arcus Biosciences and partner Gilead Sciences are discontinuing a Phase III trial for their anti-TIGIT cancer therapy, domvanalimab, after it failed to improve patient survival. The news caused Arcus stock to plunge, erasing an eight-month rally, and prompted a strategic pivot.
Eli Lilly presented updated Phase 3 data for its breast cancer drug, imlunestrant, demonstrating a notable reduction in disease progression. The results reinforce the drug's potential in a competitive oncology landscape marked by both rapid innovation and high-profile clinical setbacks.